AvidiMab®
AvidiMab® Fc engineering facilitates prolonged antibody target occupancy and/or receptor clustering.
The technology has been shown to improve avidity of anti-glycan antibodies, immune agonist antibodies and receptor blocking antibodies.
Enhanced direct cell killing by GlyMab® through increased activity. More avid glycan binding leads to cancer cell death.
AvidiMab® promotes receptor clustering thereby improving immune signalling.
AvidiMab® promotes receptor clustering thereby improving immune signalling.
- Promotes non-covalent Fc-Fc interactions of target-bound antibodies
- Facilitates receptor clustering, improved target occupancy, reduces antibody off-rate
- Increases direct killing of anti-glycan antibodies and improves efficacy of agonist antibodies
Open to licensing enquiries
commercial@scancell.co.uk
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.
